Trials Sponsors Conditions Drugs Pricing

Conditions

Parkinson's disease

Outcome Measures

Primary Outcomes (2)

Parkinson's Disease-Cognitive Rating Scale (PD-CRS)
Parkinson's Disease-Cognitive Functional Rating Scale (PD-CFRS)

Secondary Outcomes (17)

Trail Making Test A (TMT-A)
Digit Span directo (DSd)
Trail Making Test B (TMT-B)
Phonemic fluency
Boston Nomination Test reduced (BNTr)
+12 more secondary outcomes

Interventions

ARICEPT 10mg comprimidos recubiertos con películaType not reported

Registry intervention entries

These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.

Formulated product
ARICEPT 10mg comprimidos recubiertos con película
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
FILM-COATED TABLET
View registry record

Ingredients named in source formulations

The registry names these ingredients. The formulation’s exact chemical form has not been confirmed.

ARICEPT 10mg comprimidos recubiertos con película
Named ingredient: Donepezil hydrochloride
View registry record

Eligibility Criteria

Sexall

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Age between 50 and 80 years (inclusive).
Diagnosis of Parkinson's disease based on MDS criteria
Neuroimaging compatible with Parkinson's disease

Sponsors & Collaborators

Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant Pau
Type not reportedlead

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Study Sites (21)

Hospital Universitario Fundacion Alcorcon

Alcorcon, 28922, Spain

Lydia Vela Desojo+34650385989 lvela@fhalcorcon.es

Hospital La Milagrosa S.A.

Madrid, 28010, Spain

Víctor Gómez Mayordomo+34618435605 vicmayordomo@gmail.com

Hospital Universitario Ramon Y Cajal

Madrid, 28034, Spain

Juan Carlos Martínez913368397

Central Study Contacts

UICEC Sant Pau

935537796 uicec@santpau.cat

Study Design

Study Type: interventional
Phase: phase 2

Study Record Dates

First Submitted

June 5, 2024

Source record

Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: 2024-510959-35-00
Data provider: European Medicines Agency (EMA)
Normalization version: ctis-v1

Open registry record

Source retrieved: 2026-11-01 04:59:41 UTC

Documents

D1_Protocol 2024-510959-35-00 for pub

Multicenter, randomized, double-blind, and placebo-controlled clinical trial to assess the efficacy and safety of donepezil versus placebo in mild cognitive impairment associated with Parkinson's disease.

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

Conditions

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (17)

Interventions

Registry intervention entries

Ingredients named in source formulations

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (21)

Central Study Contacts

Study Design

Study Record Dates

Source record

Documents

You may not qualify if:

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Conditions

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (17)

Interventions

Registry intervention entries

Ingredients named in source formulations

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (21)

Central Study Contacts

Study Design

Study Record Dates

Source record

Documents

You may not qualify if:

Locations